 |
111 Diseases |  |
5 Trials |
|
5 Trials |  |
76 News |  |
| «12 |
- ||||| Varubi (rolapitant oral) / TerSera Therap, GSK
Enrollment closed, CINV: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Apr 30, 2014
P3, N=532, Active, not recruiting, Sponsor: Tesaro, Inc.
Recruiting --> Active, not recruiting
- || olanzapine / Generic mfg.
New P3 trial, CINV: Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Apr 15, 2014
P3, N=372, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
- ||||||| Varubi (rolapitant oral) / TerSera Therap, GSK
Trial completion: Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy (clinicaltrials.gov) - Mar 23, 2014
P3, N=1369, Completed, Sponsor: Tesaro, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Varubi (rolapitant oral) / TerSera Therap, GSK
Trial completion, CINV: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Mar 23, 2014
P3, N=555, Completed, Sponsor: Tesaro, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| temozolomide / Generic mfg.
Trial initiation date, Compliance: Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients (clinicaltrials.gov) - Mar 3, 2014
P2, N=90, Not yet recruiting, Sponsor: Duke University
Active, not recruiting --> Completed Initiation date: Oct 2013 --> Apr 2014
- | Decadron (dexamethasone) / Merck (MSD)
Trial completion: Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial (clinicaltrials.gov) - Nov 4, 2013
P3, N=1021, Completed, Sponsor: Joseph Roscoe
Initiation date: Oct 2013 --> Apr 2014 Active, not recruiting --> Completed
- ||||| temozolomide / Generic mfg.
New P2 trial, Compliance: Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients (clinicaltrials.gov) - Sep 26, 2013
P2, N=90, Not yet recruiting, Sponsor: Duke University
- granisetron oral / Generic mfg.
New P2 trial: Does local adminstration of the drug granisetron influence facial skin sensitivity? (EUDRACT) - May 13, 2013
P2, N=30, Ongoing, Sponsor: Karolinska Institutet
- cyclophosphamide / Generic mfg.
Trial completion: Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant (clinicaltrials.gov) - Aug 5, 2012
P=N/A, N=40, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | metoclopramide / Generic mfg.
Enrollment change, Adverse events: SAKK 90/95: Drugs to Reduce the Side Effects of Chemotherapy (clinicaltrials.gov) - Jul 9, 2012
P3, N=267, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Completed N=360 --> 267
- | metoclopramide / Generic mfg.
Trial completion, Adverse events: SAKK 90/95: Drugs to Reduce the Side Effects of Chemotherapy (clinicaltrials.gov) - Jul 9, 2012
P3, N=267, Completed, Sponsor: Swiss Group for Clinical Cancer Research
N=360 --> 267 Active, not recruiting --> Completed
- |||||| Varubi (rolapitant oral) / TerSera Therap, GSK
Enrollment open, CINV: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Mar 15, 2012
P3, N=530, Recruiting, Sponsor: Tesaro, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Varubi (rolapitant oral) / TerSera Therap, GSK
New P3 trial: Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy (clinicaltrials.gov) - Dec 26, 2011
P3, N=1369, Completed, Sponsor: Tesaro, Inc.
- |||||||||| Varubi (rolapitant oral) / TerSera Therap, GSK
New P3 trial, CINV: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Dec 26, 2011
P3, N=555, Completed, Sponsor: Tesaro, Inc.
- |||||||||| Varubi (rolapitant oral) / TerSera Therap, GSK
New P3 trial, CINV: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Dec 22, 2011
P3, N=530, Recruiting, Sponsor: Tesaro, Inc.